Principles of pharmacology in the eye

被引:161
作者
Awwad, Sahar [2 ,3 ,4 ]
Ahmed, Abeer H. A. Mohamed [2 ,3 ,4 ]
Sharma, Garima [2 ,3 ,4 ]
Heng, Jacob S. [3 ,4 ]
Khaw, Peng T. [3 ,4 ]
Brocchini, Steve [2 ,3 ,4 ]
Lockwood, Alastair [1 ]
机构
[1] Queen Alexandra Hosp, Dept Ophthalmol, Portsmouth PO6 3LY, Hants, England
[2] UCL Sch Pharm, London, England
[3] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, NIHR, London, England
[4] UCL Inst Ophthalmol, London, England
基金
英国医学研究理事会;
关键词
OCULAR DRUG-DELIVERY; HYDROXYPROPYL-BETA-CYCLODEXTRIN; CILIARY NEUROTROPHIC FACTOR; PLURIPOTENT STEM-CELLS; UVEITIC MACULAR EDEMA; DEXAMETHASONE INTRAVITREAL IMPLANT; TOPICALLY APPLIED STEROIDS; VITRO/IN-VIVO EVALUATION; GENE-THERAPY; IN-VITRO;
D O I
10.1111/bph.14024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The eye is a highly specialized organ that is subject to a huge range of pathology. Both local and systemic disease may affect different anatomical regions of the eye. The least invasive routes for ocular drug administration are topical (e.g. eye drops) and systemic (e.g. tablets) formulations. Barriers that subserve as protection against pathogen entry also restrict drug permeation. Topically administered drugs often display limited bioavailability due to many physical and biochemical barriers including the pre-corneal tear film, the structure and biophysiological properties of the cornea, the limited volume that can be accommodated by the cul-de-sac, the lacrimal drainage system and reflex tearing. The tissue layers of the cornea and conjunctiva are further key factors that act to restrict drug delivery. Using carriers that enhance viscosity or bind to the ocular surface increases bioavailability. Matching the pH and polarity of drug molecules to the tissue layers allows greater penetration. Drug delivery to the posterior segment is a greater challenge and, currently, the standard route is via intravitreal injection, notwithstanding the risks of endophthalmitis and retinal detachment with frequent injections. Intraocular implants that allow sustained drug release are at different stages of development. Novel exciting therapeutic approaches include methods for promoting transscleral delivery, sustained release devices, nanotechnology and gene therapy.
引用
收藏
页码:4205 / 4223
页数:19
相关论文
共 239 条
[1]   Biodegradable Ocular Inserts for Sustained Delivery of Brimonidine Tartarate: Preparation and In Vitro/In Vivo Evaluation [J].
Aburahma, Mona Hassan ;
Mahmoud, Azza Ahmed .
AAPS PHARMSCITECH, 2011, 12 (04) :1335-1347
[2]   A comprehensive insight on ocular pharmacokinetics [J].
Agrahari, Vibhuti ;
Mandal, Abhirup ;
Agrahari, Vivek ;
Trinh, Hoang M. ;
Joseph, Mary ;
Ray, Animikh ;
Hadji, Hicheme ;
Mitra, Ranjana ;
Pal, Dhananjay ;
Mitra, Ashim K. .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2016, 6 (06) :735-754
[3]   Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN [J].
Ahfat, F. G. ;
Zaidi, F. H. .
EYE, 2013, 27 (03) :289-290
[4]  
AHMED I, 1985, INVEST OPHTH VIS SCI, V26, P584
[5]   THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Catalytic receptors [J].
Alexander, Stephen P. H. ;
Fabbro, Doriano ;
Kelly, Eamonn ;
Marrion, Neil ;
Peters, John A. ;
Benson, Helen E. ;
Faccenda, Elena ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. ;
Aldrich, R. ;
Attali, B. ;
Back, M. ;
Barnes, N. M. ;
Bathgate, R. ;
Beart, P. M. ;
Becirovic, E. ;
Biel, M. ;
Birdsall, N. J. ;
Boison, D. ;
Brauner-Osborne, H. ;
Broeer, S. ;
Bryant, C. ;
Burnstock, G. ;
Burris, T. ;
Cain, D. ;
Calo, G. ;
Chan, S. L. ;
Chandy, K. G. ;
Chiang, N. ;
Christakos, S. ;
Christopoulos, A. ;
Chun, J. J. ;
Chung, J. -J. ;
Clapham, D. E. ;
Connor, M. A. ;
Coons, L. ;
Cox, H. M. ;
Dautzenberg, F. M. ;
Dent, G. ;
Douglas, S. D. ;
Dubocovich, M. L. ;
Edwards, D. P. ;
Farndale, R. ;
Fong, T. M. ;
Forrest, D. ;
Fowler, C. J. ;
Fuller, P. ;
Gainetdinov, R. R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :5979-6023
[6]   Modeling of corneal and retinal pharmacokinetics after periocular drug administration [J].
Amrite, Aniruddha C. ;
Edelhauser, Henry F. ;
Kompella, Uday B. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (01) :320-332
[7]  
Awwad S, 2013, INVEST OPHTH VIS SCI, V54
[8]   Sustained release ophthalmic dexamethasone: In vitro in vivo correlations derived from the PK-Eye [J].
Awwad, Sahar ;
Day, Richard M. ;
Khaw, Peng T. ;
Brocchini, Steve ;
Fadda, Hala M. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 522 (1-2) :119-127
[9]   The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development [J].
Awwad, Sahar ;
Lockwood, Alastair ;
Brocchini, Steve ;
Khaw, Peng T. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (10) :3330-3342
[10]   Gene therapy progress and prospects: the eye [J].
Bainbridge, J. W. B. ;
Tan, M. H. ;
Ali, R. R. .
GENE THERAPY, 2006, 13 (16) :1191-1197